Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study

Cephalalgia : an International Journal of Headache
S EversA Frese

Abstract

Botulinum toxin A has been suggested to be effective in the prophylactic treatment of migraine. However, only very few randomized, double-blind, placebo-controlled studies are available. We designed such a study with a specific focus on different injection sites. Sixty patients with a migraine according to the criteria of the International Headache Society were randomly assigned to receive either placebo in the frontal and neck muscles, or to receive 16 U botulinum toxin A in the frontal muscles and placebo in the neck muscles, or to receive in total 100 U botulinum toxin A in the frontal and neck muscles. The observation period was 3 months. In both treatment groups, 30% of patients showed a reduction of migraine frequency in month 3 by at least 50% compared with baseline, in the placebo group 25% of the patients showed such a reduction (P = 0.921). There were no significant differences between the three study groups with respect to reduction of migraine frequency, number of days with migraine, and the number of total single doses to treat a migraine attack. In the post hoc analysis, the reduction of all accompanying symptoms was significantly higher in the 16 U treatment group compared with the placebo group. In the 100 U tre...Continue Reading

References

Mar 1, 1988·Cephalalgia : an International Journal of Headache·F SorgeP Carrieri
Feb 13, 2001·Cephalalgia : an International Journal of Headache·P Tfelt-HansenUNKNOWN International Headache Society Clinical Trials Subcommittee
Dec 12, 2001·Cephalalgia : an International Journal of Headache·W B YoungT D Rozen
Jun 5, 2002·Plastic and Reconstructive Surgery·Bahman GuyuronJanine Davis
Aug 7, 2002·Current Treatment Options in Neurology·Ninan T. Mathew, Alex O. Kaup
Nov 8, 2002·Cephalalgia : an International Journal of Headache·S EversI-W Husstedt

❮ Previous
Next ❯

Citations

Nov 13, 2007·Journal of Neural Transmission·W J Schulte-Mattler, E Leinisch
Mar 9, 2006·Current Neurology and Neuroscience Reports·Nabih M Ramadan
Jul 10, 2009·Current Pain and Headache Reports·Avi Ashkenazi
Mar 8, 2008·Current Treatment Options in Neurology·Markus SchürksPeter Goadsby
Dec 20, 2008·Current Treatment Options in Neurology·Avi Ashkenazi, Stephen Silberstein
Dec 20, 2008·Current Treatment Options in Neurology·Mark Obermann, Hans-Christoph Diener
May 17, 2005·Medical Hypotheses·Gary L Cohen
Nov 6, 2007·Nature Clinical Practice. Neurology·Peter J Goadsby
Dec 2, 2008·Nature Clinical Practice. Neurology·Bahman Jabbari
Feb 15, 2012·Nature Reviews. Neurology·Hans-Christoph DienerStephen D Silberstein
Mar 3, 2010·Plastic and Reconstructive Surgery·Seymour Solomon
Sep 28, 2010·Plastic and Reconstructive Surgery·Theodore A KungPaul S Cederna
Jun 27, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies· P S Sándor
Jan 19, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·W J Schulte-Mattler, J C Martinez-Castrillo
Aug 28, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S EversUNKNOWN European Federation of Neurological Societies
Jun 17, 2006·Cephalalgia : an International Journal of Headache·S Evers, J Olesen
Apr 24, 2007·Cephalalgia : an International Journal of Headache·Alexander Mauskop
Feb 18, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Tamara PringsheimWerner J Becker
Jan 26, 2012·Neuropsychiatric Disease and Treatment·Carrie E Robertson, Ivan Garza
Sep 1, 2006·Neuropsychiatric Disease and Treatment·Ivan Garza, Jerry W Swanson
Jul 29, 2006·Drugs & Aging·Paola SarchielliPaolo Calabresi
May 14, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Andy Pickett
Jun 12, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Tamara PringsheimUNKNOWN Canadian Headache Society Prophylactic Guidelines Development Group
Jun 9, 2005·Expert Review of Neurotherapeutics·Stephen H Landy, Bob L Lobo
Mar 15, 2006·Expert Review of Neurotherapeutics·Julia Samton, Alexander Mauskop
Sep 23, 2006·Expert Opinion on Investigational Drugs·Stefan Evers
Aug 31, 2006·Expert Opinion on Emerging Drugs·Peter J Goadsby
May 26, 2006·Expert Opinion on Pharmacotherapy·Sheena Aurora
Jan 22, 2010·Expert Opinion on Biological Therapy·Roger K Cady
Oct 4, 2006·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Vinod Kumar Gupta
Oct 1, 2011·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Bahman Jabbari, Duarte Machado
Aug 25, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Joel R SaperUNKNOWN BoNTA-009 Study Group
Apr 20, 2005·Headache·F Michael Cutrer
Nov 23, 2006·Headache·Ninan T Mathew
Apr 12, 2007·Headache·Nabih M Ramadan
Sep 22, 2007·Headache·Marcela Romero-Reyes, Steven Graff-Radford
Feb 27, 2009·Cranio : the Journal of Craniomandibular Practice·Roberta de Abreu VenancioCamila Zamperini
Nov 3, 2005·The Annals of Pharmacotherapy·Crystal N Chilson, Sherrill J Brown
Sep 19, 2015·Headache·Kasra MaasumiStewart J Tepper

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.